Alpha¹ by KaimenConfidential

Kaimen Rigor review

Home-Based Care for Hypertension in Rural South Africa.

Siedner MJ, Magula N, Mazibuko L, Sithole N, Castle A, Nxumalo S, Manyaapelo T, Abrahams-Gessel S, Gareta D, Orne-Gliemann J, Baisley K, Bachmann M, Gaziano TA

DOI: 10.1056/NEJMoa2509958
Record issued: 2026-08-10
Engine: 7.29.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/d4cc8d15-77e9-441c-97cf-21b2dfbe6168 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability not met−0.5★
ReportingKey resources partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is systolic blood pressure (SBP), a surrogate for cardiovascular outcomes. The paper does not demonstrate target engagement at the intervention dose—i.e., it does not measure or show that the intervention changed the intended behavioral mediators (e.g., medication adherence, self-monitoring frequency) to confirm that the intervention produced the desired effect. While it cites a validated link between SBP reduction and hard clinical outcomes, target engagement is not shown.
“The primary outcome was systolic BP at 6 months.”
Find in source
02Data and code not shared
highDisclosurereviewer-assessedFull detail
No data availability statement, repository deposit, or code sharing is reported. The paper only provides trial registration numbers, which do not constitute a data availability mechanism.
03Internal contradictions in the reported numbers
mediumArithmeticreviewer-assessedFull detail
The text states '20 severe adverse events in 21 participants' but Table 2 lists 4+7+10=21 severe adverse events, suggesting a miscount.
Text: 'There were 20 severe adverse events in 21 participants'; Table 2: severe adverse events: SOC 4 (1.6%), CHW 7 (2.7%), eCHW+ 10 (3.9%)
Table 2reviewer’s wording

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 204DisclosureReporting gaps 05AvailabilityNone found 06Copyedit11 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a methodologically strong randomized trial: sound randomization with concealment, blinded outcome assessment, a pre-specified power analysis, named ethics approvals, trial registration, and effect sizes with confidence intervals throughout. Its principal weaknesses are the complete absence of a data availability statement, threshold-only primary p-values with unidentified statistical software, incompletely identified antihypertensive drugs, and no reference to a reporting guideline. Two verifiable numerical issues (a 20-vs-21 severe adverse event contradiction and an anomalous Table 1 travel-time SD) warrant correction.

Three independent reviewer runs converged on 6 of 8 dimensions; they split on ethical approvals (2 pass vs 1 warn, resolved to pass on the strength of named-committee and SAHPRA approval) and statistical analysis (2 pass vs 1 warn, resolved to warn per the explicit threshold-only p-value rubric). Verification components confirmed trial registration, 8/8 recomputed statistics consistent with no decision errors, no retracted or unresolvable citations, and a live, consistent protocol link; the statistics component's coverage is limited to tests reported with a test statistic/df or effect+CI, so unrecomputed analyses remain unverified, not confirmed.

Numerical inconsistencies

1 finding · worst medium

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 8 tests: 8 consistent, 0 inconsistent; 8 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Recompute two-tailed p-value for CHW vs SOC difference in mean systolic BP at 6 months from the reported estimate and 95% CI.
“Compared to SOC, mean systolic BP at 6 months was lower in the CHW arm (−7.9mm Hg, 95%CI −10.5, −5.3, P<0.001)”
Find in source
Taken as given: The estimate is −7.9 mmHg and the 95% CI is (−10.5, −5.3); The CI is two-sided at the 95% level; The reported P<0.001 corresponds to a two-tailed test of the difference
Method: Used pCI(estimate, low, high, log=0) to derive the two-tailed p-value from the effect estimate and its 95% CI.
How we recomputed it: pCI(-7.9, -10.5, -5.3, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Recompute two-tailed p-value for eCHW+ vs SOC difference in mean systolic BP at 6 months from the reported estimate and 95% CI.
“eCHW+ arm (−9.1mmHg, 95%CI −11.7, −6.4, P<0.001)”
Find in source
Taken as given: The estimate is −9.1 mmHg and the 95% CI is (−11.7, −6.4); The CI is two-sided at the 95% level; The reported P<0.001 corresponds to a two-tailed test of the difference
Method: Used pCI(estimate, low, high, log=0) to derive the two-tailed p-value from the effect estimate and its 95% CI.
How we recomputed it: pCI(-9.1, -11.7, -6.4, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Recompute two-tailed p-value for the relative risk of hypertension control at 6 months (CHW vs SOC) from the reported RR and 95% CI.
“76.9% in the CHW arm (RR 1.33 vs SOC, 95%CI 1.18–1.51)”
Find in source
Taken as given: The RR is 1.33 and the 95% CI is (1.18, 1.51); The CI is two-sided at the 95% level; The RR is on a ratio scale, so log=1
Method: Used pCI(estimate, low, high, log=1) to derive the two-tailed p-value from the log-ratio effect estimate and its 95% CI.
How we recomputed it: pCI(1.33, 1.18, 1.51, 1)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Recompute two-tailed p-value for the relative risk of hypertension control at 6 months (eCHW+ vs SOC) from the reported RR and 95% CI.
“82.8% in the eCHW+ arm (RR 1.44 vs SOC, 95%CI 1.28–1.62)”
Find in source
Taken as given: The RR is 1.44 and the 95% CI is (1.28, 1.62); The CI is two-sided at the 95% level; The RR is on a ratio scale, so log=1
Method: Used pCI(estimate, low, high, log=1) to derive the two-tailed p-value from the log-ratio effect estimate and its 95% CI.
How we recomputed it: pCI(1.44, 1.28, 1.62, 1)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 2, 3
Primary outcome: mean systolic BP difference at 6 months, CHW vs SOC arm
“mean systolic BP at 6 months was lower in the CHW arm (−7.9mm Hg, 95%CI −10.5, −5.3, P<0.001)”
Find in source
Taken as given: The estimate is the adjusted mean difference from linear regression.; The 95% CI is two-sided and based on a normal approximation.; The reported p-value is two-tailed.
Method: Two-tailed p-value from estimate and 95% CI using normal approximation (pCI function).
How we recomputed it: pCI(-7.9, -10.5, -5.3, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 2, 3
Primary outcome: mean systolic BP difference at 6 months, eCHW+ vs SOC arm
“mean systolic BP at 6 months was lower in the ... eCHW+ arm (−9.1mmHg, 95%CI −11.7, −6.4, P<0.001)”
Find in source
Taken as given: The estimate is the adjusted mean difference from linear regression.; The 95% CI is two-sided and based on a normal approximation.; The reported p-value is two-tailed.
Method: Two-tailed p-value from estimate and 95% CI using normal approximation (pCI function).
How we recomputed it: pCI(-9.1, -11.7, -6.4, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Secondary outcome: relative risk of hypertension control at 6 months, CHW vs SOC
“Relative risk for hypertension control vs SOC: 1.33 (1.18, 1.51)”
Find in source
Taken as given: The estimate is a relative risk (ratio) from logistic regression with marginal standardization.; The 95% CI is two-sided and based on a normal approximation on the log scale.; The reported p-value is two-tailed.
Method: Two-tailed p-value from log-relative risk and its 95% CI using normal approximation (pCI with log=1).
How we recomputed it: pCI(1.33, 1.18, 1.51, 1)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Secondary outcome: relative risk of hypertension control at 6 months, eCHW+ vs SOC
“Relative risk for hypertension control vs SOC: 1.44 (1.28, 1.62)”
Find in source
Taken as given: The estimate is a relative risk (ratio) from logistic regression with marginal standardization.; The 95% CI is two-sided and based on a normal approximation on the log scale.; The reported p-value is two-tailed.
Method: Two-tailed p-value from log-relative risk and its 95% CI using normal approximation (pCI with log=1).
How we recomputed it: pCI(1.44, 1.28, 1.62, 1)

mediuminternal contradiction
The text states '20 severe adverse events in 21 participants' but Table 2 lists 4+7+10=21 severe adverse events, suggesting a miscount.
Text: 'There were 20 severe adverse events in 21 participants'; Table 2: severe adverse events: SOC 4 (1.6%), CHW 7 (2.7%), eCHW+ 10 (3.9%)
Table 2reviewer’s wording
lowinternal contradiction
The text states '20 severe adverse events' but the table sums to 21 total adverse events (4+7+10) and the breakdown '8 deaths and 13 hospitalizations' also sums to 21.
“There were 20 severe adverse events in 21 participants, including 8 deaths and 13 hospitalizations”
Table 2Find in source

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

10 major claims checked against the paper's own evidence: all adequately supported.

partialReviewer 1
These results support home-based hypertension care in similar low-resource settings.
The study is limited to two clinics in one rural region of South Africa, which the authors acknowledge; the generalization to other low-resource settings is reasonable but extends beyond the direct evidence.
Evidence: Single-region trial in rural KwaZulu-Natal; authors note 'Studies in urban areas and settings without CHW programs will be needed.'
“These results in a historically disadvantaged community support home-based hypertension care in similar low-resource settings”
Discussion ¶1Find in source
partialReviewers 1, 2
The 8–10mmHg reduction in mean systolic BP observed in the intervention arms has been associated with a 15–25% reduction in risk of heart attack, stroke, and heart failure.
The BP reduction is supported by the results, but the risk reduction is an extrapolation from external literature, not measured in this study.
Evidence: The paper cites prior studies for this association, not its own data.
“The 8–10mmHg reduction in mean systolic BP observed in the intervention arms has been associated with a 15–25% reduction in risk of heart attack, stroke, and heart failure.”
Discussion ¶1Find in source
partialReviewer 3
Home-based hypertension care can be recommended for similar low-resource settings.
The study provides strong evidence from two clinics in one rural region, but generalizability to other countries or urban areas is not proven. The authors acknowledge this limitation, so the claim is partially supported.
Evidence: Discussion states the results support home-based care in similar settings, but also notes limitations of single-country, two-clinic design.
These results in a historically disadvantaged community support home-based hypertension care in similar low-resource settings... Our study is limited by its conduct in two clinics in one region of a single country.
Discussion ¶1reviewer’s wording
supportedReviewers 1, 2, 3
Home-based hypertension care led to significant reductions in systolic BP and improvements in hypertension control in South Africa.
The headline conclusion is directly supported by the primary outcome results (6-month systolic BP differences and control RRs with CIs).
Evidence: Primary outcome: CHW arm −7.9 mmHg (95%CI −10.5, −5.3) and eCHW+ −9.1 mmHg (95%CI −11.7, −6.4) vs SOC; hypertension control RR 1.33 and 1.44.
“Home-based hypertension care led to significant reductions in systolic BP and improvements in hypertension control in South Africa.”
ConclusionFind in source
supportedReviewers 1, 3
Improved BP with home-based care appeared to persist at 12 months.
The 12-month data show sustained reductions (−10.3 and −10.5 mmHg vs SOC) and higher control rates, supporting the claim.
Evidence: 12-month systolic BP differences −10.3 (95%CI −12.6, −8.0) and −10.5 (95%CI −12.8, −8.2); control RR 1.43 and 1.48.
“Improved BP with home-based care appeared to persist at 12 months.”
Table 2Find in source
supportedReviewer 1
Retention in care remained >95% in both intervention arms.
Retention at 6 and 12 months is reported as 97.3–99.6% in the intervention arms, directly supporting the claim.
Evidence: Retention in care at 6 months: 98.1% (CHW) and 99.6% (eCHW+); at 12 months: 97.3% and 97.7%.
“Retention in care remained >95% in both intervention arms.”
Table 2Find in source
supportedReviewer 2
Our study was unique among this body of research as the only one evaluating a home-based intervention in which participants received BP monitoring and visitation by lay healthcare workers.
The paper compares its design to prior studies and identifies that no other study combined all these elements.
Evidence: Discussion compares to COBRA BPS, barbershop study, etc., and notes the unique combination.
“Our study was unique among this body of research as the only one evaluating a home-based intervention in which participants received BP monitoring and visitation by lay healthcare workers.”
Discussion ¶4Find in source
supportedReviewer 2
These results in a historically disadvantaged community support home-based hypertension care in similar low-resource settings.
The study population is described as disadvantaged, and the results are positive and consistent across subgroups.
Evidence: Table 1 and subgroup analyses show benefits across sociodemographic groups.
These results in a historically disadvantaged community support home-based hypertension care in similar low-resource settings.
Discussion ¶5reviewer’s wording
supportedReviewer 3
The magnitude of benefit was similar in most sub-groups.
Subgroup analyses (Figure 2) show consistent benefit across most subgroups, with a possible greater effect in those with higher baseline BP. The claim is supported by the presented data.
Evidence: Figure 2 and text: 'The magnitude of benefit ... was similar in most sub-groups. There appeared to be a greater effect in those with a systolic BP at enrollment ≥160mmHg.'
The magnitude of benefit in terms of mean systolic BP reduction at 6 months observed in the intervention groups compared to SOC was similar in most sub-groups. There appeared to be a greater effect in those with a systolic BP at enrollment ≥160mmHg versus those with a systolic BP at enrollment of 140–160 mmHg.
Results ¶4reviewer’s wording
supportedReviewer 3
The intervention is unique among prior research as the only one evaluating a home-based intervention with BP monitoring and lay healthcare worker visitation.
The Discussion contrasts with prior studies and explicitly states that no prior study combined all these elements. The evidence for uniqueness is based on the literature review presented.
Evidence: Discussion paragraph 3: 'Our study was unique among this body of research as the only one evaluating a home-based intervention in which participants received BP monitoring and visitation by lay healthcare workers.'
“Our study was unique among this body of research as the only one evaluating a home-based intervention in which participants received BP monitoring and visitation by lay healthcare workers.”
Discussion ¶3Find in source

Premise concern: surrogate not validated for clinical benefit.

INADEQUATESurrogate endpoint
The primary endpoint is systolic blood pressure (SBP), a surrogate for cardiovascular outcomes. The paper does not demonstrate target engagement at the intervention dose—i.e., it does not measure or show that the intervention changed the intended behavioral mediators (e.g., medication adherence, self-monitoring frequency) to confirm that the intervention produced the desired effect. While it cites a validated link between SBP reduction and hard clinical outcomes, target engagement is not shown.
“The primary outcome was systolic BP at 6 months.”
Find in source
ADEQUATEEffect size
The reduction in systolic BP of 8–10 mmHg is clinically meaningful and is explicitly anchored to a 15–25% reduction in risk of heart attack, stroke, and heart failure.
“The 8–10mmHg reduction in mean systolic BP observed in the intervention arms has been associated with a 15–25% reduction in risk of heart attack, stroke, and heart failure.”
Find in source

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

lowother
In Table 1, the travel time to clinic SD for the CHW arm (187) is far larger than the SOC (43) and eCHW+ (33) arms, and the total SD (112) does not reflect the individual arm SDs, suggesting a possible data anomaly or extreme outliers in that arm.
“47 (43) | 52 (187) | 41 (33 | 47 (112)”
Table 1Find in source

Reporting gaps

2 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Eight Dimensions6 pass · 1 warn · 1 fail

The background cites poor hypertension control rates and structural barriers in South Africa, and the Discussion compares the study to prior meta-analyses and individual trials, noting that no prior study combined multiple strategies. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper clearly establishes the scientific premise: poor hypertension control in low-resource settings, identifies structural barriers, and cites prior work showing scarcity of efficacy data for home-based programs.

Evidence

“data on the efficacy of such programs are scarce”

Introduction ¶2Find in source

“Home-based BP management with remote monitoring has been proposed to address these barriers”

IntroductionFind in source

“no study in that review combined multiple strategies to address the multifactorial barriers to chronic disease care”

Discussion ¶2Find in source

PASSReviewer 2· 95% conf

The paper clearly establishes the scientific foundation by citing prior work, providing a logical rationale, and addressing limitations of prior research.

Evidence

“Home-based BP management with remote monitoring has been proposed to address these barriers, but data on the efficacy of such programs are scarce.”

Introduction ¶2Find in source

“Elevated blood pressure (BP) is the leading risk factor for preventable mortality, responsible for approximately 10 million deaths each year.”

Introduction ¶1Find in source

“In contrast to our study, no study in that review combined multiple strategies to address the multifactorial barriers to chronic disease care.”

Discussion ¶2Find in source

PASSReviewer 3· 95% conf

The paper clearly establishes the scientific premise by citing prior research on hypertension burden and poor control, acknowledges limitations of prior work, and provides a logical rationale for the study.

Evidence

“Although numerous low cost, effective therapies are available, disease control rates are poor, particularly among populations with structural barriers to healthcare.”

Introduction ¶1Find in source

“Home-based BP management with remote monitoring has been proposed to address these barriers, but data on the efficacy of such programs are scarce.”

Introduction ¶2Find in source

paraphrase[Discussion, paragraph 3]

“The Discussion contrasts prior studies that used text messaging or decision support alone, noting that none combined multiple strategies as in this study.”

Randomization used REDCap with block allocation and stratification. Blinding of outcome assessors is described. Power analysis is detailed. Inclusion/exclusion criteria are pre-specified. The analysis population (ITT) and handling of missing data (censoring, LOCF sensitivity) are stated.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Randomization, allocation concealment, blinding of outcome assessors, power analysis, and eligibility criteria are all clearly described; open-label design is stated.

Evidence

“Those eligible who provided informed consent were randomized 1:1:1 in blocks of nine to one of the three trial arms using the randomization module in REDCap.”

MethodsFind in source

“Study staff not involved with the intervention program and blinded to study arm conducted home visits at 6 and 12 months”

MethodsFind in source

paraphrase[Methods, Sample Size]

“we had >80% power to detect a 5 mmHg difference between arms in mean systolic BP at 6 months, allowing for 20% loss to follow-up... and a two-tailed alpha of 2.5%”

PASSReviewer 2· 95% conf

All applicable design elements are adequately reported: randomization method, unit, blinding of outcome assessors, power analysis, and inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Trial Design and Eligibility Criteria]

“randomized 1:1:1 in blocks of nine using the randomization module in REDCap.”

“Study staff not involved with the intervention program and blinded to study arm conducted home visits at 6 and 12 months after enrollment in all three arms to collect outcome data.”

MethodsFind in source

paraphrase[Methods, Sample Size]

“With a target enrollment of 774 participants (258 per arm), we had >80% power to detect a 5 mmHg difference between arms in mean systolic BP at 6 months, allowing for 20% loss to follow-up, a correlation between baseline and follow-up measurements of 0.5, and a two-tailed alpha of 2.5% to account for multiple comparisons.”

PASSReviewer 3· 95% conf

The study design is rigorous: randomization, sample size calculation, inclusion/exclusion criteria, and blinding of outcome assessors are all adequately reported.

Evidence

“Those eligible who provided informed consent were randomized 1:1:1 in blocks of nine to one of the three trial arms using the randomization module in REDCap.”

MethodsFind in source

“Study staff not involved with the intervention program and blinded to study arm conducted home visits at 6 and 12 months after enrollment in all three arms to collect outcome data.”

MethodsFind in source

Sex is reported (76% women). Age, BMI, HIV, diabetes, and GFR are given. Demographics include race, education, employment, asset index, and travel time. Sex justification is not applicable as both sexes were enrolled.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Sex, age, BMI, HIV status, diabetes, education, employment, and water access are reported in detail in Table 1.

Evidence

“the mean age was 62 years (SD 12) and 76% (588/774) were women”

Table 1Find in source

“One hundred percent of participants were of black African descent”

Table 1Find in source

PASSReviewer 2· 95% conf

Sex, age, health status, and detailed demographics are reported adequately.

Evidence

“76% were women”

AbstractFind in source

“The mean age was 62 years (SD 12) and 76% (588/774) were women.”

Results ¶2Find in source

paraphrase[Results, paragraph 2]

“One hundred percent of participants were of black African descent, reflecting the demographics of people with hypertension in this rural region South Africa.”

PASSReviewer 3· 95% conf

Biological variables and subject characteristics are comprehensively reported, including age, sex, health status, and socioeconomic factors.

Evidence

“At enrollment, the mean age was 62 years (SD 12) and 76% (588/774) were women.”

Results ¶1Find in source

paraphrase[Table 1]

“Age (years), mean (SD) | 62 (12) | 63 (12) | 62 (11) | 62 (12) | ... Body mass index (kg/m2), mean (SD) | 29.3 (7.5) | 29.8 (7.1) | 30.0 (7.1) | 29.7 (7.2)”

“Eleven percent (87/774) were employed and 15% (112/774) had access to running water in their household.”

Table 1Find in source

The trial was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee, Mass General Brigham IRB, and the South African Health Products Regulatory Authority. All participants provided signed informed consent. The trial is registered with ClinicalTrials.gov and SAHPRA. A data safety monitoring board conducted an interim assessment.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

Named ethics committees and regulatory authority approved the trial, and signed informed consent was obtained from all participants.

Evidence

“The trial was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee, the Institutional Review Board of Mass General Brigham and by the South African Health Products Regulatory Authority.”

MethodsFind in source

“All participants provided signed informed consent.”

MethodsFind in source

WARNReviewer 2· 90% conf

Ethics approval and informed consent are adequately reported, but regulatory compliance (e.g., Declaration of Helsinki) is not explicitly stated.

Evidence

Ethical Considerations, paragraph 1Find in source

“All participants provided signed informed consent.”

Ethical Considerations, paragraph 1Find in source

absence[Ethical Considerations]

Regulatory compliance statement is missing.

PASSReviewer 3· 95% conf

Ethical approvals from named committees and informed consent are clearly documented, along with regulatory compliance.

Evidence

MethodsFind in source

“All participants provided signed informed consent.”

MethodsFind in source

“SAHPRA Trial Number : N20211201 SANCTR Number: DOH-27-112022-4895”

MethodsFind in source

BP machines are identified by manufacturer and model (Omron Digital M3, BlipCare). The mobile application is identified (iMarketing Consultants). However, the statistical software used for analysis is not reported. Other resource categories (antibodies, cell lines, organisms) are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 70% conf

BP devices and the mobile application are well identified, but the anti-hypertensive medications are named without dose/regimen/manufacturer details.

Evidence

“participants received an automated BP machine (Omron Digital M3. Kyoto, Japan)”

MethodsFind in source

“record BP readings into a mobile health application on their phones (iMarketing Consultants, Windhoek, Namibia”

MethodsFind in source

paraphrase[Methods, Study Arms]

“The three principle anti-hypertensive therapies... were hydrochlorothiazide, lisinopril, and amlodipine.”

WARNReviewer 2· 85% conf

The BP machines and mobile application are identified, but statistical software is not identified.

Evidence

“In the CHW arm, participants received an automated BP machine (Omron Digital M3. Kyoto, Japan)”

MethodsFind in source

paraphrase[Methods, Study Arms]

“a mobile health application on their phones (iMarketing Consultants, Windhoek, Namibia)”

absence[Methods, Statistical Analyses]

Statistical software is not identified.

WARNReviewer 3· 85% conf

The investigational products (drugs and devices) are partially identified; the manufacturers of the antihypertensive drugs are not specified, while the BP machines and mobile app are adequately identified.

Evidence

“The three principle anti-hypertensive therapies available in the public sector in South Africa and used in this study were hydrochlorothiazide, lisinopril, and amlodipine.”

MethodsFind in source

“In the CHW arm, participants received an automated BP machine (Omron Digital M3. Kyoto, Japan)”

MethodsFind in source

“CHWs visited participants within one week of enrollment and approximately monthly thereafter to record BP readings into a mobile health application on their phones (iMarketing Consultants, Windhoek, Namibia, see for full details and screenshots of the application).”

MethodsFind in source

Tests are named (linear regression, logistic regression, marginal standardization). Exact p-values are reported for primary comparisons. Effect sizes with 95% CIs are provided. Data presentation includes per-group n, means, CIs, and proportions. Software is not identified, but this is a single omission among six applicable criteria, giving 83% adequacy.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 75% conf

Statistical methods are well described with effect sizes and CIs, but primary p-values are reported only as thresholds (P<0.001) and statistical software is not identified.

Evidence

“P-value vs SOC arm at 6 months | N/A | <0.001 | <0.001”

Table 2Find in source

paraphrase[Abstract; Results]

“mean systolic BP at 6 months was lower in the CHW arm (−7.9mm Hg, 95%CI −10.5, −5.3)”

absence[Methods, Statistical Analyses]

Statistical software is not identified.

PASSReviewer 2· 90% conf

All applicable statistical criteria are adequately reported except software identification, which is missing but does not lower the overall status below pass.

Evidence

“We fit linear regression models to estimate the difference between arms in mean systolic BP at 6 months.”

Statistical analysisFind in source

paraphrase[Table 2]

“P-value vs SOC arm at 6 months: <0.001”

“mean systolic BP at 6 months was lower in the CHW arm (−7.9mm Hg, 95%CI −10.5, −5.3, P<0.001)”

AbstractFind in source

PASSReviewer 3· 85% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported. However, exact p-values are not provided (only thresholds), and the statistical software is not identified.

Evidence

“For the primary outcome, we fit linear regression models to estimate the difference between arms in mean systolic BP at 6 months. The model included terms for treatment arm, baseline systolic BP and randomization strata (clinic and use of hypertension medication at enrollment).”

Statistical analysisFind in source

“Difference between arms at 6 months vs SOC | Reference | −7.9 (−10.5, −5.3) | −9.1 (−11.7, −6.4)”

Table 2Find in source

“P-value vs SOC arm at 6 months | N/A | <0.001 | <0.001”

Table 2Find in source

The paper does not include a data availability statement, nor does it mention any repository deposit for the trial data. No custom code is shared. The trial registration numbers are provided, but no statement about data access or sharing is made. This is a significant omission for a clinical trial, especially given the potential for reproducibility.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 80% conf

No data availability statement is present in the manuscript; the protocol is referenced to supplementary material but no data access route is described.

Evidence

absence[Entire manuscript]

No data availability statement is present.

“Study protocol and analysis plan versions and changes are available”

Supplementary materialFind in source

FAILReviewer 2· 90% conf

No data availability statement, repository deposit, or code sharing is reported.

Evidence

absence[Entire manuscript]

No data availability statement is present.

absence[Entire manuscript]

No repository deposit is mentioned.

absence[Entire manuscript]

No code sharing is mentioned.

FAILReviewer 3· 95% conf

No data availability statement, repository deposit, or code sharing is reported. The paper only provides trial registration numbers, which do not constitute a data availability mechanism.

Evidence

absence[Entire manuscript]

No data availability statement is present in the manuscript.

absence[Entire manuscript]

No repository deposit or accession numbers are mentioned.

absence[Entire manuscript]

No custom code is shared or referenced.

Methods are detailed enough for replication. Trial registration number is provided. All pre-specified outcomes are reported. Limitations are discussed. Conclusions are proportional to evidence. Funding and conflicts of interest are stated. A reporting guideline (e.g., CONSORT) is not explicitly referenced.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

Methods are detailed, the trial is registered, limitations are thoroughly discussed, and funding/COI are disclosed; no reporting checklist is referenced.

Evidence

“Trial Registration: NCT05492955”

FootnotesFind in source

“Our study is limited by its conduct in two clinics in one region of a single country.”

Discussion ¶5Find in source

absence[Methods; Footnotes]

No reporting guideline checklist is referenced.

PASSReviewer 2· 90% conf

Most reporting transparency criteria are met; only a reporting guideline checklist is not referenced.

Evidence

“Trial Registration: NCT05492955”

FootnotesFind in source

“Our study is limited by its conduct in two clinics in one region of a single country.”

Discussion ¶5Find in source

“This IMPACT-BP trial was funded by the US National Institutes of Health (R01 HL144848) and the Wellcome Trust (227167/A/23/Z).”

FundingFind in source

PASSReviewer 3· 90% conf

The manuscript is well-reported with detailed methods, trial registration, outcome reporting, limitations, proportional conclusions, and funding/COI. The only gap is the lack of a reference to a specific reporting guideline (e.g., CONSORT).

Evidence

“Trial Registration: NCT05492955 (https://clinicaltrials.gov/show/NCT05492955) , registered August 5, 2022 SAHPRA Trial Number : N20211201 SANCTR Number: DOH-27-112022-4895”

FootnotesFind in source

“Our study is limited by its conduct in two clinics in one region of a single country.”

Discussion ¶5Find in source

paraphrase[Funding and Footnotes]

“This IMPACT-BP trial was funded by the US National Institutes of Health (R01 HL144848) and the Wellcome Trust (227167/A/23/Z). ... Disclosure forms provided by the authors are available with the full text of this article at NEJM.org”

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT05492955

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 25 references by DOI: 1 verified — 24 no DOI (shown, not verified).

NO DOI
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Global report on hypertension: the race against a silent killer
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The global epidemiology of hypertension
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Understanding barriers and facilitators to integrated HIV and hypertension care in South Africa
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A formative evaluation of potential barriers and facilitators to inform effective implementation of a community-based hypertension care program in rural South Africa: The IMPACT-BP trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Protocol: Implementation Evaluation of a Combination Intervention for Sustainable Blood Pressure Control in Rural KwaZulu-Natal, South Africa (IMPACT BP): A three-arm, unblinded, parallel group individually randomized clinical trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Primary Healthcare Standard Treatment Guideline and Essential Medicine List
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk Predictions
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The REDCap consortium: Building an international community of software platform partners
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
South African hypertension practice guideline 2014
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
EQ-SD: a measure of health status from the EuroQol Group
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Estimating predicted probabilities from logistic regression: different methods correspond to different target populations
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The Effectiveness of Telemedicine in Hypertension Management of Adults in Rural Communities: A Systematic Review and Meta-Analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Comparative Effectiveness of Implementation Strategies for Blood Pressure Control in Hypertensive Patients: A Systematic Review and Meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A Community-Based Intervention for Managing Hypertension in Rural South Asia
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Group Medical Visits and Microfinancial Intervention for Patients with Diabetes or Hypertension in Kenya
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The South African National Integrated Men’s Health Strategy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

1 data/code link checked; 1 live.

datahttps://clinicaltrials.gov/show/NCT05492955LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

11 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 11 minor suggestions below.

11 copyedit issues flagged: mostly consistency, punctuation, typo.

MINORtypoResults, paragraph 1
“CWH (n=257)”
→ CHW (n=257)
Abbreviation for community health worker arm is misspelled as CWH.
MINORpunctuationTable 1, Travel time to clinic
“41 (33”
→ 41 (33)
Missing closing parenthesis for the eCHW+ arm SD.
MINORpunctuationTable 1, HIV status row
“133 51.8%)”
→ 133 (51.8%)
Missing opening parenthesis for the CHW arm percentage.
MINORconsistencyResults; Table 2
“P-value<0.001”
→ P<0.001
Inconsistent formatting of p-value notation across abstract, results, and tables.
MINORotherEnd of manuscript
“supp app”
→ Remove or format as a proper supplementary-appendix label
Stray 'supp app' text appears at the end of the manuscript after the disclosure forms.
MINORconsistencyTable 1, Travel time to clinic (eCHW+ arm)
“41 (33”
→ 41 (33)
Missing closing parenthesis.
MINORconsistencyTable 1, HIV status row (CHW arm)
“133 51.8%)”
→ 133 (51.8%)
Missing opening parenthesis.
MINORconsistencyResults, paragraph 5
“There were 20 severe adverse events in 21 participants”
→ There were 21 severe adverse events in 21 participants
The sum of severe adverse events in Table 2 is 21 (4+7+10), not 20. The text should match the table.
MINORpunctuationTable 1, Travel time row
“41 (33”
→ 41 (33)
Missing closing parenthesis for the mean and SD of the eCHW+ arm.
MINORconsistencyThroughout
“enrolment / enrollment”
→ Choose one spelling and use consistently.
Both 'enrollment' and 'enrolment' appear; 'enrollment' is used more frequently and is standard in US English.
MINORclarityMethods, Study Arms
“In the second intervention arm (eCHW+), participants received a BP machine with short message service text message capability (BlipCare, Carematrix Inc, Chicago, IL).”
→ Consider adding a brief explanation of how the text message transmission works.
The description is clear but could be slightly expanded for reproducibility.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust at its core — the design, randomization, blinding, registrations, and effect sizes are sound, and every recomputed statistic was consistent — so an informed reader can have reasonable confidence in the headline findings. However, the absence of any data availability statement severely limits reproducibility, and three verifiable issues warrant erratum or re-verification: the severe-adverse-event count (text says 20, Table 2 sums to 21), the anomalous Table 1 travel-time SD for the CHW arm (187 vs 43/33, inconsistent with the overall SD of 112), and the threshold-only p-values with unnamed statistical software. A reader should weigh these reporting gaps, not the trial's internal validity, when relying on the results.

1.
HIGHdata code
Add a data availability statement specifying a repository or managed-access mechanism (e.g., Vivli, YODA, or controlled access on request with a data-sharing agreement) for de-identified participant-level data, and state the trial's data-access policy.
A clinical trial with no data availability statement is a major reproducibility gap that an informed reader will weigh heavily.
2.
HIGHrigor
Correct the severe adverse event count in Results paragraph 5 — '20 severe adverse events in 21 participants' — to match Table 2, which sums to 21 (4+7+10); this internal contradiction warrants an erratum.
A demonstrable internal contradiction between the text and the safety table is a factual error that must be reconciled in the published record.
3.
HIGHrigor
Verify the Table 1 travel-time-to-clinic SD for the CHW arm (187) against source data; it is far larger than the SOC (43) and eCHW+ (33) arms and inconsistent with the overall SD (112), suggesting a possible data anomaly or extreme outliers.
An implausible per-arm dispersion that disagrees with the pooled value signals a possible data error a reader cannot resolve without clarification.
4.
MEDIUMstatistics
Identify the statistical software (name and version, e.g., Stata 17 or R 4.2) used for all analyses in the Statistical Analyses section.
Unidentified software prevents replication of the analyses and is a straightforward reporting fix.
5.
MEDIUMstatistics
Report exact p-values (e.g., P=0.0003) for the primary and key secondary outcomes, or explicitly state the journal convention for reporting P<0.001.
Threshold-only p-values are imprecise reporting; exact values allow readers to apply their own multiplicity or Bayesian interpretations.
6.
MEDIUMrigor
Identify the manufacturer/source and dose/regimen of the antihypertensive drugs (hydrochlorothiazide, lisinopril, amlodipine) in the Methods, Study Arms section.
The drugs are the trial's investigational products; naming them without manufacturer or dose/regimen is incomplete resource identification.
7.
MEDIUMreporting
Reference the CONSORT 2010 statement as the reporting guideline and include a completed CONSORT checklist (and ideally a CONSORT flow diagram) as supplementary material.
A randomized trial without a referenced reporting-guideline checklist is a minor but easily closed transparency gap.
8.
MEDIUMethics
Add an explicit statement of compliance with the Declaration of Helsinki and/or ICH-GCP in the Ethical Considerations section.
Named committee and SAHPRA approval already demonstrate compliance, but an explicit framework statement removes residual ambiguity for readers.
9.
LOWcopyedit
Fix the 'CWH (n=257)' typo to 'CHW (n=257)' in Results, paragraph 1.
A misspelled arm abbreviation is a factual typo that confuses the arm labels.
10.
LOWcopyedit
Fix missing parentheses in Table 1: the travel-time SD '41 (33' should read '41 (33)' and the HIV-status value '133 51.8%)' should read '133 (51.8%)'.
Broken parenthetical formatting in Table 1 makes values ambiguous.
11.
LOWcopyedit
Remove or properly format the stray 'supp app' text appearing at the end of the manuscript after the disclosure forms.
Stray editorial text in the published record looks unprofessional and should be cleaned or relabeled.
12.
LOWcopyedit
Standardize the spelling of 'enrollment'/'enrolment' and the p-value notation (P<0.001 vs P-value<0.001) consistently across the manuscript.
Inconsistent terminology and notation are minor polish items that improve readability.

Full text (29,080 chars)Analyzed: Aug 10, 2026

RigorReviewer 1

RigorReviewer 2

RigorReviewer 3

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Home-Based Care for Hypertension in Rural South Africa.

Siedner MJ, Magula N, Mazibuko L, Sithole N, Castle A, Nxumalo S, Manyaapelo T, Abrahams-Gessel S, Gareta D, Orne-Gliemann J, Baisley K, Bachmann M, Gaziano TA

DOI

10.1056/NEJMoa2509958

Record issued

2026-08-10

Engine

7.29.0

Exported

2026-09-20